Skip to main content
SpringerLink
Log in

How to measure leukotrienes in man

  • Chapter
Book cover Leukotrienes

  • 59 Accesses

Abstract

The involvement of leukotrienes (LTs) in asthma mainly concerns the cysteinylleukotrienes (cys-LTs, LTC4, D4 and E4), which are chemical mediators of events in the airways as part of an asthmatic attack1. There is still a debate in the literature whether the proinflammatory compound LTB4, formed from the common unstable epoxide intermediate LTA4, also contributes to the airway inflammation associated with asthma2.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dahlén S-E. Leukotrienes and related lipoxygenase products. In Barnes Pi, Rodger 1W, Thomson NC, Barnes PJ, Thomson NC, editors Asthma Basic mechanisms and clinical management. London: Academic Press. 1988.213–30.

    Google Scholar 

  2. Christie P, Barnes N. Leukotriene B4 and asthma. Thorax. 1996. 12: 1171–3.

    Article  Google Scholar 

  3. Kumlin M. Analytical methods for the measurements of leukotrienes and other eicosanoids in biological samples from asthmatic subjects J Chromatography A. 1996; 725.29–40.

    Article  Google Scholar 

  4. MacGlashan DW Jr, Schleimer RP, Peters SP, et al. Generation of leukotnenes by purified human lung mast cells. J Clin Invest. 1982; 70: 747–51.

    Article  PubMed  CAS  Google Scholar 

  5. Kumlin M, Dahlén S-E. Characteristics of formation and further metabolism of leukotnenes in the chopped human lung. Biochim Biophys Acta. 1990; 1044: 201–10

    Article  PubMed  CAS  Google Scholar 

  6. Dahlén S-E, Hansson G, Hedqvist P, Björck T, Granström E, Dahlén B. Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4 and E4. Proc Natl Acad Sci USA. 1983; 80.1712–16.

    Article  PubMed  Google Scholar 

  7. Picado C, Ramis I, Rosellò J, et al Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Resp Dis. 1992; 145: 65–9.

    Article  PubMed  CAS  Google Scholar 

  8. Ramis I, Catafau JR, Serra J. Bulbena O. Picado C, Gelpi E. In vivo release of 15-HETE and other arachidonic acid metabolites in nasal secretions during early allergic reactions. Prostaglandins. 1991; 42 411–20

    PubMed  CAS  Google Scholar 

  9. Lam S, Chan H, LeRiche JC, Chan-Yeung M. Salan H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol. 1988; 81 711–17.

    Article  PubMed  CAS  Google Scholar 

  10. Wardlaw AJ, Hay H, Cromwell O, Collins JV, Kay AB. Leukotrienes, LTC4 and LTE4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases J Allergy Clin Immunol. 1989; 84 19–26

    Article  PubMed  CAS  Google Scholar 

  11. Westcott JY, Johnston K, Batt RA, Wenzel SE, Voelkel NF Measurement of peptidoleukotrienes in biological fluids. J Appl Physiol. 1990; 68 2640–8

    PubMed  CAS  Google Scholar 

  12. Bisgaard H, Robinson C, Romeling F, Mygind N, Church M, Holgate S Leukotnene C4 and histamine in early allergic reaction in the nose. Allergy. 1988; 43: 219–27.

    Article  PubMed  CAS  Google Scholar 

  13. Wenzel SE, Larsen GL, Johnston K. Voelkel NF, Westcott JY. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Resp Dis. 1990; 142. 112–19.

    Article  PubMed  CAS  Google Scholar 

  14. Szczeklik A, Sladek K. Dworski R, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics Am J Resp Crit Care Med 1996,154: 1608–14.

    Article  PubMed  CAS  Google Scholar 

  15. Volovitz B, Osur SL, Bernstein JM, Ogra PL Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. J Allergy Clin Immunol. 1988; 82: 414–18.

    Article  PubMed  CAS  Google Scholar 

  16. Volovitz B, Nathanson I, DeCastro G, et al. Relationship between leukotriene C4 and an uteroglobin-like protein in nasal and tracheobronchial mucosa of children Implication in acute respiratory illnesses. Int Arch Allergy Appl immunol 1988, 86: 420–5.

    Article  PubMed  CAS  Google Scholar 

  17. Granstrom E, Kumlin M. Metabolism of prostaglandins and lipoxygenase products: Relevance for eicosanoid assay. In: Benedetto C, McDonald RG, Nigam S. et al., editors. Prostaglandins and related substances. A practical approach Oxford. IRL Press, 1987; 5–27.

    Google Scholar 

  18. Heavey DJ, Soberman RJ, Lewis RA, Spur B, Austen KF. Critical consideration in the development of an assay for sulfidopeptide leukotrienes in plasma Prostaglandins 1987; 33.693–708.

    PubMed  CAS  Google Scholar 

  19. Sampson AP, Castling DP, Green CP, Price JF. Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch Dis Child. 1995; 73: 221–5

    Article  PubMed  CAS  Google Scholar 

  20. Shrratsuki N, Uyama O, Kitada O, et al. Effects of hydrocortisone and aminophylline on plasma leukotriene C4 levels in patients during an asthmatic attack. Prostaglandins Leukotrienes Essential Fatty Acids. 1990; 40: 285--9

    Article  Google Scholar 

  21. Schwartzberg S, Shelov S, Van Praag D. Blood leukotriene levels during the acute asthma attack in children. Prostaglandins Leukotrienes Med. 1987; 26: 143–55.

    Article  CAS  Google Scholar 

  22. Kumlin M, Stensvad F, Larsson L, Dahlén B, Dahlén S-E. Validation and application of a new simple strategy for measurements of leukotriene E4 in human urine Clin Exp Allergy. 1995; 25.467–79

    Article  PubMed  CAS  Google Scholar 

  23. Huber M, Kastner S. Schölmerich J, Gerok W, Keppler D. Analysis of cysteinyl leukotrienes in human urine. Enhanced excretion in patients with liver cirrhosis and hepatorenal syndrome. Eur J Clin Invest. 1989, 19: 53–60.

    PubMed  CAS  Google Scholar 

  24. Mayatepek E, Pecher G. Increased excretion of endogenous urinary leukotriene E4 in extrahepatic cholestasis. Clin Chim Acta. 1993. 218. 185–92.

    Article  PubMed  CAS  Google Scholar 

  25. Uemura M, Buchholz U, Kojima H, et al Cysteinyl leukotrienes in the urine of patients with liver diseases. Hepatology. 1994; 20.804–12

    Article  PubMed  CAS  Google Scholar 

  26. Richter L. Hesselbarth N, Eitner K, Bosseckert H, Krell H. Increased biliary secretion of cysteinyl-leukotrienes in human bile duct obstruction. J Hepatol. 1996; 25. 725–32.

    Article  PubMed  CAS  Google Scholar 

  27. Ishikawa T, Muller M, Klunemann C, Schaub T, Keppler D. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S.coniugates. J Biol Chem. 1990, 265: 19279–86.

    PubMed  CAS  Google Scholar 

  28. Orning L, Kagser L, Hammarström S. In vivo metabolism of leukotriene C4 in man: Urinary excretion of leukotriene E4. Biochem Biophys Res Commun. 1985; 130: 214–20.

    Article  PubMed  CAS  Google Scholar 

  29. Huber M, Müller J, Leier I, et al. Metabolism of cysteinyl leukotrienes in monkey and man. Eur J Biochem. 1990; 194.309–15.

    Article  PubMed  CAS  Google Scholar 

  30. Maltby NH, Taylor GW, Ritter JM, Moore K, Fuller RW, Dollery CT Leukotriene C4 elimination and metabolism in man. J Allergy Clin Immunol 1990; 85.3–9

    Article  PubMed  CAS  Google Scholar 

  31. Sala A, Voelkel N, Maclouf J, Murphy RC Leukotriene E4 elimination and metabolism in normal human subjects. J Biol Chem 1990, 265 21771–8

    PubMed  CAS  Google Scholar 

  32. Verhagen J, Bel EH, Kline GM, Sterk PJ, Bruynzeel PLB, Veldink GA, Vliegenthart JFG. The excretion of leukotriene E4 into urine following inhalation of leukotriene D4 by human individuals Biochem Biophys Res Commun. 1987; 148: 864–8.

    Article  PubMed  CAS  Google Scholar 

  33. Tagari P, Rasmussen JB, Delorme D. et al. Comparison of urinary leukotriene E4 and 16-carboxytetranordihydro leukotriene E4 excretion in allergic asthmatics after inhaled antigen. Eicosanoids.1990:3. 75–80.

    PubMed  CAS  Google Scholar 

  34. Kumlin M, Dahlén B, Björck T, Zetterstrom O, Granström E, Dahlén S-E. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Resp Dis. 1992; 146.96–103

    Article  PubMed  CAS  Google Scholar 

  35. Christie PE, Tagari P. Ford-Hutchinson AW. et al Increased urinary LTE4 excretion following inhalation of LTC3, and LTE4 in asthmatic subjects. Eur Resp J 1994; 7: 907–13.

    CAS  Google Scholar 

  36. Westcott J, Sloan S, Wenzel S. Immunofiltration purification for urinary leukotriene quantification. Anal Biochem 1997; 248: 202–10.

    Article  PubMed  CAS  Google Scholar 

  37. Dahlén B, Kumlin M, Margolskee DJ, et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J. 1993; 6: 1018–26.

    PubMed  Google Scholar 

  38. Kumlin M, Dahlén B. The challenge procedure influences the magnitude of allergeninduced urinary excretion of leukotriene E4. Am J Resp Crit Care Med. 1997; 155: A665.

    Google Scholar 

  39. Dahlén B, Zetterström O. Comparison of bronchial and per oral provocation with aspirin in aspirin-sensitive asthmatics. Eur Resp J. 1990; 3: 527–34.

    Google Scholar 

  40. Granstrom E, Kumlin M, Kindahl H, Radioimmunoassay of eicosanoids. In Benedetto C, McDonald-Gibson RG, Nigam S, Slater TF, editors. Prostaglandins and related substances A practical approach. Oxford: IRL Press. 1987: 167–95.

    Google Scholar 

  41. Tagari P, Ethier D, Carry M, et al. Measurements of urinary leukotrienes by reverse-phase liquid chromatography and radioimmunoassay. Clin Chem. 1989, 35: 388–91.

    PubMed  CAS  Google Scholar 

  42. Drazen JM, O’Brien J, Sparrow D, et al Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Resp Dis. 1992; 146: 104–8.

    Article  PubMed  CAS  Google Scholar 

  43. Tsikas D, Fauler J, Gutzki FM, Röder Th, Bestmann HJ, Frölich JC. Gas chromatographic-mass spectrometric determination of leukotriene E4 in human urine using deuterium-labelled leukotriene E4 standards. J Chromatogr. 1993; 622: 1–7.

    PubMed  CAS  Google Scholar 

  44. Nicoll-Griffith D, Zamboni R. Rasmussen JB, Ethier D, Charleson S, Tagari P. BIG-fully automated sample treatment high-performance liquid chromatography and radioimmunoassay for leukotriene E4 in human urine from asthmatics. J Chromatogr. 1990; 526. 341–54

    PubMed  CAS  Google Scholar 

  45. Rasmussen JB, Eriksson L-O, Margolskee DJ, Tagari P, Williams VC, Andersson K-E Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol. 1992; 90. 193–201.

    Article  PubMed  CAS  Google Scholar 

  46. Smith CM, Christie PE, Hawksworth RJ, Thien F, Lee TH. Urinary leukotriene E4 levels after allergen and exercise challenge in bronchial asthma. Am Rev Resp Dis. 1991; 144: 1411–13.

    Article  PubMed  CAS  Google Scholar 

  47. Smith CM, Hawksworth RJ, Thien FCK, Christie PE, Lee TH. Urinary leukotriene E4 in bronchial asthma. Eur Resp J. 1992: 5: 693–9.

    CAS  Google Scholar 

  48. Manning PJ, Rokach J, Malo J-L, et al. Urinary leukotriene E4 levels during early and late asthmatic responses. J Allergy Clin Immunol. 1990; 86: 211–20.

    Article  PubMed  CAS  Google Scholar 

  49. Westcott JY, Smith HR, Wenzel SE, et al, Urinary leukotriene E4 in patients with asthma. Effects of airways reactivity and sodium cromoglycate. Am Rev Resp Dis. 1991; 143: 1322–8.

    Article  PubMed  CAS  Google Scholar 

  50. Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects. Am Rev Resp Dis. 1992; 146: 1531–4.

    Article  PubMed  CAS  Google Scholar 

  51. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 1993; 119 1059–66.

    Article  PubMed  CAS  Google Scholar 

  52. Taylor GW, Taylor I, Black P, et al. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989; i 584–8.

    Article  Google Scholar 

  53. Sladek K, Dworski R, Fitzgerald GA, et al Allergen-stimulated release of thromboxane A2 and leukotriene E4 in humans. Effects of indomethacin. Am Rev Resp Dis. 1990; 141: 1441–5

    Article  PubMed  CAS  Google Scholar 

  54. Asano K, Lilly CM, O’Donell WJ, et al. Diurnal variation of urinary leukotriene E4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. J Allergy Clin Immunol. 1995; 96: 643–51.

    Article  PubMed  CAS  Google Scholar 

  55. Bellia V, Bonanno A, Cibella F, et al. Urinary leukotriene Ea in the assessment of nocturnal asthma J Allergy Clin Immunol. 1996, 97: 735–41.

    CAS  Google Scholar 

  56. Wenzel SE, Trudeau JB, Kaminsky DA, Cohn J, Martin RJ, Westcott JY Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Resp Crit Care Med. 1995; 152: 897–905.

    Article  PubMed  CAS  Google Scholar 

  57. Szczeklik A. Aspirin-induced asthma. Pathogenesis and clinical presentation. Allergy Proc. 1992, 13 163–73.

    Article  PubMed  CAS  Google Scholar 

  58. Christie PE, Tagari P, Ford-Hutchinson AW et al Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Resp Dis. 1991; 143. 1025–9

    Article  PubMed  CAS  Google Scholar 

  59. Nasser SMS, Patel M, Bell GS, Lee TH. The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am J Resp Crit Care Med. 1995, 151: 1326–30.

    Article  PubMed  CAS  Google Scholar 

  60. Denzlinger C, Habert C, Wilmanns W. Cysteinyl leukotriene production in anaphylactic reactions. Int Arch Allergy Immunol. 1995; 108: 158–64.

    Article  PubMed  CAS  Google Scholar 

  61. Friedman BS. Bel EH, Buntinx A, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses Am Rev Resp Dis. 1993; 147: 839–44.

    Article  PubMed  CAS  Google Scholar 

  62. Hui KP, Taylor IK, Taylor GW, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46: 184–9.

    Article  PubMed  CAS  Google Scholar 

  63. Nasser SMS, Bell GS, Hawksworth RJ, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses Thorax. 1994; 49: 743–8.

    CAS  Google Scholar 

  64. Knapp HR, Sladek K, Fitzgerald GA. Increased excretion of leukotriene E4 during aspirin-induced asthma, J Lab Clin Med. 1992; 119: 48–51.

    PubMed  CAS  Google Scholar 

  65. Sladek K, Szczeklik A. Cystemyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Resp J. 1993; 6: 391–9.

    CAS  Google Scholar 

  66. Nasser SMS, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma Thorax. 1994; 49: 749–56.

    CAS  Google Scholar 

  67. Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE, prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Resp Crit Care Med. 1996; 153: 572–5.

    Article  PubMed  CAS  Google Scholar 

  68. Taylor IK, Wellings R, Taylor GW, Fuller RW. Urinary leukotriene E4 excretion in exercise-induced asthma. J Appl Physiol. 1992; 73: 743–8.

    PubMed  CAS  Google Scholar 

  69. Kikawa Y, Miyanomae T, Inoue Y, et al. Urinary leukotriene E4 after exercise challenge in children with asthma. J Allergy Clin Immunol. 1992; 89. 1111–19.

    Article  PubMed  CAS  Google Scholar 

  70. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O’Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571: A potent leukotriene D4-receptor antagonist. N Engl J Med. 1990; 323: 1736–9.

    Article  PubMed  CAS  Google Scholar 

  71. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Resp Dis. 1992; 145: 746–9.

    Article  PubMed  CAS  Google Scholar 

  72. Robuschi M, Riva E, Fucella LM, et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo. Am Rev Resp Dis. 1992; 145.1285–8.

    Article  PubMed  CAS  Google Scholar 

  73. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: A 5-lipoxygenase inhibitor. Am J Resp Crit Care Med. 1996; 153: 931–5.

    Article  PubMed  CAS  Google Scholar 

  74. O’Sullivan S, Kumlin M, Larsson I, Roqut A, Dahlén B, Dahlén S-E. Urinary excretion of leukotriene E4 and the mast cell marker 9α,1 β-prostaglandin F4 during allergen-induced early and late phase asthmatic reactions. Am J Resp Crit Care Med. 1996; 153: A250.

    Article  Google Scholar 

  75. O’Sullivan S, Roquet A, Dahlén B, Kumlin M, Dahlén S-E Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions. Submitted.

    Google Scholar 

  76. Roquet A, Dahlén B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Resp Crit Care Med. 1997, 155. 1856–63.

    Article  PubMed  CAS  Google Scholar 

  77. Taylor IK, O’Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337. 690–4.

    Article  PubMed  CAS  Google Scholar 

  78. Hansson G, Lindgren J, Dahlén S-E, I Hedgvist P, Samuelsson B Identification and biological activity of novel w-oxidized metabolites of leukotriene B4 from human leukocytes. FEBS Lett. 1981 130 107–12.

    Article  PubMed  CAS  Google Scholar 

  79. Schönfeld W, Schluter B, Hilger R, König W. Leukotriene generation and metabolism in isolated human lung macrophages. Immunology. 1988.65.529–36

    PubMed  Google Scholar 

  80. Kumlin M, Falck JR, Raud J, Harada Y, Dahlén S-E. Granstrom E. Identification and biological activity of dihydro-leukotriene B4 A prominent metabolite of leukotriene B4 in the human lung. Biochem Biophys Res Commun. 1990, 170. 23–9.

    Article  PubMed  CAS  Google Scholar 

  81. Diamant Z, Timmers M, van der Veen H, et al The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol. 1995; 95: 42–51.

    Article  PubMed  CAS  Google Scholar 

  82. O’Sullivan S, Dahlén B, Dahlén S-E, Kumlin M Increased urinary excretion of the prostaglandin D2 metabolite 9α.1 I (β-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced bronchoconstriction. J Allergy Clin Immunol. 1996, 98: 421–32.

    Article  PubMed  Google Scholar 

  83. Liston T, Roberts L. Metabolic fate of radiolabelcd prostaglandin D2, in a normal human male volunteer J Biol Chem. 1985; 260: 13172–80.

    PubMed  CAS  Google Scholar 

  84. Davidson D. Drafta D, Wilkens BA. Elevated urinary leukotriene E4 in chronic lung disease of extreme prematurity Am J Resp Cnt Care Med. 1995; 151: 841–5.

    Article  CAS  Google Scholar 

  85. Cook AJ, Yuksel B, Sampson AP, Greenough A, Price JF Cysteinyl leukotriene involvement in chronic lung disease in premature infants. Eur Respir J. 1996, 9. 1907–12

    Article  PubMed  CAS  Google Scholar 

  86. Fauler J, Neumann CH, Tsikas D, Frölich JC Enhanced synthesis of cysteinyl leukotrienes in atopic dermatitis. Br J Dermatol 1993; 128. 627–30.

    Article  PubMed  CAS  Google Scholar 

  87. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation. 1992; 85 230–6

    Article  PubMed  CAS  Google Scholar 

  88. Allen SP, Sampson AP, Piper PJ, Chester AIL Ohri SK, Yacoub MH Enhanced excretion of urinary leukotriene E4 in coronary artery disease and after coronary artery bypass surgery. Coronary Artery Dis. 1993; 4: 899–904

    Article  CAS  Google Scholar 

  89. Fauler J, Thon A, Tsikas D, von der Hardt H. Frölich JC. Enhanced synthesis of cysteinyl leukotrienes in juvenile rheumatoid arthritis. Arthritis Rheum 1994, 37: 93–7.

    Article  PubMed  CAS  Google Scholar 

  90. Hackshaw KV, Voelkel NF, Thomas RB, Westcott JY. Urine leukotriene E4 levels are elevated in patients with active systemic lupus erythematosus. J Rheumatol. 1992; 19. 252–8.

    PubMed  CAS  Google Scholar 

  91. Hackshaw KV, Yuhong SHI, Brandwein SR, Jones K, Westcott JY. A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus. J Rheumatol. 1995, 22: 462–8.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Kumlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Merck Frosst Canada, Inc., Pointe-Claire-Dorval, Quebec, Canada

    Ian Rodger

  2. The William Harvey Research Institute, Saint Bartholomew’s Hospital Medical College, London, UK

    Jack Botting

  3. Asthma and Allergy Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

    Sven-Erik Dahlén

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Kumlin, M. (1998). How to measure leukotrienes in man. In: Rodger, I., Botting, J., Dahlén, SE. (eds) Leukotrienes. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4880-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-4880-1_5

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6045-5

  • Online ISBN: 978-94-011-4880-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation